reports
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Wim Lewi
- Jacob Mekhael
Galapagos Model update
Galapagos began 2024 with the completion of the transfer of the Jyseleca business to Alfasigma for € 50m upfront, € 120m in milestones and mid-single to mid-double digit royalties. This is expected to result in cost savings for Galapagos, and the company guides for FY24 cash burn of € 280-320m, coming in lower vs. FY23's € 415m. We update our model post FY23, replacing Jyseleca sales with royalties and milestones, and adjust our OPEX estimates to reflect the anticipated cost savings, landing at ...
Galapagos showcases innovative approach in hematological cancer care w...
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT) Mechelen, Belgium; 4 April 2024, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that four abstracts, including two oral presentations on encore preliminary clinical and translational data for its seven-day vein-to-vein CAR-T product...
Galapagos publishes 2023 annual report and announces Annual and Extrao...
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings Publication of annual report for financial year 2023Annual Shareholders’ Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary Shareholders’ Meeting resolutions include approval of renewal of authorized capital and issuance of Gilead Subsequent Warrant B Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2023 and an...
Galapagos publiceert 2023 jaarverslag en kondigt jaarlijkse Gewone Alg...
Galapagos publiceert 2023 jaarverslag en kondigt jaarlijkse Gewone Algemene en Buitengewone Algemene Aandeelhoudersvergaderingen aan Publicatie van jaarverslag over boekjaar 2023Voorstellen van besluit van de Gewone Algemene Vergadering omvatten de goedkeuring van een herzien remuneratiebeleid en de (her)benoeming van bestuurdersVoorstellen van besluit van de Buitengewone Algemene Vergadering omvatten de goedkeuring van de hernieuwing van het toegestaan kapitaal en van de uitgifte van de Gilead Subsequent Warrant B Mechelen, België; 28 maart 2024, 21:01 CET; gereglementeerde informatie – G...
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Thomas Vranken
- Wim Hoste
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent D...
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation. Andrew Dickinson is Gilead's Chief Financial Officer (CFO) and replaces Daniel O’Day, Gilead’s Chairman and Chief Executive Officer (CEO), who was a member of the Galapagos Board of Directors from 22 October 2019 to 26 March 2024. Mr. Dickinson joined...
Galapagos benoemt Andrew Dickinson tot Niet-Uitvoerend, Niet-Onafhanke...
Galapagos benoemt Andrew Dickinson tot Niet-Uitvoerend, Niet-Onafhankelijk Bestuurder van haar Raad van Bestuur Mechelen, België; 26 maart 2024; 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) heeft vandaag aangekondigd dat de Raad van Bestuur tijdens haar vergadering van 26 maart 2024 de heer Dickinson heeft gecoöpteerd als Niet-Uitvoerend, Niet-Onafhankelijk Bestuurder. Andrew Dickinson is Gilead's Chief Financial Officer (CFO) en vervangt Daniel O'Day, Gilead's voorzitter en Chief Executive Officer (CEO), die lid was van de Raad van Bestuur van Galapagos van 22 oktober 2019 tot 26 maa...
- Juan Ros-Padilla
NK IMERYS SA
SOP SOPRA STERIA GROUP SA
F3C SFC ENERGY AG
POM PLASTIC OMNIUM SE
ISS ISS A/S
FII LISI SA
FNAC FNAC DARTY SA
HOT HOCHTIEF AG
ATE ALTEN SA
COFB COFINIMMO SA
COR CORTICEIRA AMORIM SGPS SA
BRNL BRUNEL INTERNATIONAL N.V.
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
GLPG GALAPAGOS NV
PSG PROSEGUR COMPANIA DE SEGURIDAD SA
TEC TECHNIPFMC PLC
CASH PROSEGUR CASH SA
2CRSI 2CRSI SA
TMV TEAMVIEWER AG
HAG HENSOLDT AG
- Juan Ros-Padilla
NK IMERYS SA
SOP SOPRA STERIA GROUP SA
F3C SFC ENERGY AG
POM PLASTIC OMNIUM SE
ISS ISS A/S
FII LISI SA
FNAC FNAC DARTY SA
HOT HOCHTIEF AG
ATE ALTEN SA
COFB COFINIMMO SA
COR CORTICEIRA AMORIM SGPS SA
BRNL BRUNEL INTERNATIONAL N.V.
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
GLPG GALAPAGOS NV
PSG PROSEGUR COMPANIA DE SEGURIDAD SA
TEC TECHNIPFMC PLC
CASH PROSEGUR CASH SA
2CRSI 2CRSI SA
TMV TEAMVIEWER AG
HAG HENSOLDT AG
- Damien Choplain
- Martial Descoutures
Galapagos : The end of the year was marked by the exit of Jyseleca, th...
>Cost control already in place - Galapagos reported its full-year 2023 results after the US market closed. After the effective sale of Jyseleca to Alfasigma last January, the publication is not so clear-cut between consolidated activities and discontinued operations. Group revenues came to € 783.5m, compared with € 545m, including € 112m from Jyseleca. The Jyseleca business made a positive contribution to net profit, with net profit from the now discontinued operation...
- Damien Choplain
- Martial Descoutures
Galapagos : Une fin d’année marquée par la sortie de Jyseleca, arrêt d...
>Un contrôle des coûts déjà mis en place - Galapagos publiait après la fermeture du marché US ses résultats annuels. Après la vente effective de Jyseleca à Alfasigma en janvier dernier, la publication n’est pas si limpide entre les activités consolidées et les opérations arrêtées. Les revenus du groupe ressortent ainsi à 783.5 M€ vs 545 M€ att en incluant notamment 112 M€ de Jyseleca. L'activité de Jyseleca a contribué positivement au résultat net, avec un bénéfice n...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Galapagos FIRST LOOK: FY23 results in line, SLE CAR-T plans removed fr...
Galapagos reported FY23 results with cash of € 3.7b, cash burn of € 415m, and FY24 cash burn guidance of € 280-320m. A pipeline update included the decision to not continue development of CD19 CAR-T in SLE due to strategic reasons, and we're keen to learn more in this afternoon's conference call. The CAR-T trials in oncology continue, and additional data in 2024 could confirm the strong, but early dataset in more patients, and provide insight into durability. We reiterate our Accumulate rating a...
- David Seynnaeve
- PhD
Galapagos - Cash burn in line, CD19 CAR-T for rSLE dropped
*Last night, GLPG published its FY23 results, reporting Jyseleca® net sales (EUR 112m) and cash burn (EUR 415m) in line with guidance and CSS. Also, GLPG guided for a lower (vs. ‘23) 2024 cash burn of EUR 280-320m.*For strategic reasons (i.e. crowded competitive landscape), GLPG axed the CD19 CAR-T ‘5101 program for rSLE. Timeline of filing of IND applications for CD19 CAR-Ts not reiterated (H1 '24 guidance at Q3 update). We expect to hear more about this during today's call at 2pm CET...
Galapagos announces full year 2023 results and outlook for 2024
Galapagos announces full year 2023 results and outlook for 2024 Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023Operational cash burni of €414.8 million, within guidance 2023 and year-to-date key updates: Transferred Jyseleca® business, including approximately 400 positions, to Alfasigma S.p.A.Achieved encouraging data from ongoing Phase 1/2 studies with CD19 CAR-T product candidates, GLPG5101 in rrNHL and GLPG5201, in rrCLL, with or without RT...
Galapagos kondigt 2023 jaarresultaten en vooruitzichten 2024 aan
Galapagos kondigt 2023 jaarresultaten en vooruitzichten 2024 aan Financiële kerngetallen voor het hele jaar 2023: Netto groepsomzet van €783,5 miljoen in 2023, inclusief €112,3 miljoen nettoverkopen voor Jyseleca® Geldmiddelen en kortlopende financiële investeringen van €3,7 miljard per 31 december 2023 Operationele cash burni van €414,8 miljoen, wat in lijn der verwachtingen is 2023 en year-to-date belangrijkste updates : Jyseleca® business, inclusief ongeveer 400 posities, overgedragen aan Alfasigma S.p.A.Bemoedigende resultaten voor lopende fase 1/2-studies met CD19 CAR-T productka...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Sharad Kumar S.P
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Galapagos presents at EBMT-EHA annual meeting 2024
Galapagos presents at EBMT-EHA annual meeting 2024 Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) to present new preliminary translational data and previously disclosed data at the European Society for Blood and Marrow Transplantation (EBMT)-European Hematology Association (EHA) 6th European CAR T-cell meeting taking place from 15–17 February 2024 in Valencia, Spain. The preliminary trans...
Galapagos presenteert op de jaarlijkse EBMT-EHA meeting van 2024
Galapagos presenteert op de jaarlijkse EBMT-EHA meeting van 2024 Toont betekenisvolle vooruitgang in gedecentraliseerde CAR T-cel productie en presenteert translationele en klinische gegevens van lopende fase 1/2 CD19 CAR-T studies Mechelen, België; 15 februari 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) presenteert preliminaire translationele data en eerder bekendgemaakte data op de European Society for Blood and Marrow Transplantation (EBMT)-European Hematology Association (EHA) 6th European CAR T-cell meeting die plaatsvindt van 15-17 februari 2024 in Valencia, Spanje. ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.